The expression of podocalyxin in patients with diabetic nephropathy and its clinical significance
10.3760/cma.j.issn.1673-4904.2013.10.005
- VernacularTitle:足细胞标志蛋白检测在糖尿病肾病中的临床应用价值
- Author:
Xiaowen CHAI
;
Xuening ZHANG
;
Li LI
- Publication Type:Journal Article
- Keywords:
Diabetic nephropathies;
Podocytes;
Podocalyxin
- From:
Chinese Journal of Postgraduates of Medicine
2013;(10):14-16
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the expression ofpodocalyxin(PCX) in patients with diabetic nephropathy (DN) and its clinical significance.Methods A total of 68 patients with DN were enrolled as DN group.Another 20 healthy person were selected as control group.The patients with DN were divided into three sub-groups:normal albuminuria group(＜ 30 mg/g,group A),microalbuminuria group(≥30 mg/g but ＜ 300 mg/g,group B) and macroalbuminuria group (≥ 300 mg/g,group C).The level of urinary PCX was measured with enzyme-linked immunosorbent assay.Results The level of urinary PCX,serum creatinine and blood urea nitrogen in DN group was higher than that in control group [(27.44 + 6.87) μ g/L vs.(3.52 +1.13) μ g/L,(154.82 ± 11.54) μ mol/L vs.(82.56 ± 5.71) μ mol/L,(8.79 ± 0.58) mmol/L vs.(4.23 ± 0.34)mmol/L,P ＜0.01].The level of urinary PCX in group A,B,C was (18.04 ±4.12),(23.58 ±5.43),(32.18 ± 6.05) μ g/L,and there was significant difference among three groups (P ＜ 0.05).The level of serum creatinine and blood urea nitrogen was (138.54 + 8.66),(142.16 ± 11.74),(165.13 ± 12.85) μ mol/L and (8.48 ± 0.43),(8.56 ± 0.61),(10.04 + 1.17) mmol/L in group A,B,C,there was no significant difference between group A and group B(P＞ 0.05),but there was significant difference between group A and group C,or between group B and group C (P ＜ 0.05).Conclusion The high-level expression of urinary PCX is found in DN patients,which maybe play a key role in the early diagnosis and assessment of the progression of DN.
